Shares of Ascentage Pharma Group International (NASDAQ:AAPG – Get Free Report) hit a new 52-week high on Friday . The company traded as high as $22.28 and last traded at $22.28, with a volume of 6414 shares. The stock had previously closed at $20.20.
Wall Street Analyst Weigh In
Separately, JPMorgan Chase & Co. began coverage on shares of Ascentage Pharma Group International in a research note on Thursday. They issued an “overweight” rating for the company.
Check Out Our Latest Report on AAPG
Ascentage Pharma Group International Stock Performance
Ascentage Pharma Group International Company Profile
Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.
Read More
- Five stocks we like better than Ascentage Pharma Group International
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- JPMorgan: The ‘NVIDIA of Banking’ Poised for More Gains?
- What is the Nasdaq? Complete Overview with History
- Buy the Chewy Stock Reversal? Here’s Why Now Is the Time
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Ibotta Stock: Why the Buyback Looks Like a Bullish Bet
Receive News & Ratings for Ascentage Pharma Group International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascentage Pharma Group International and related companies with MarketBeat.com's FREE daily email newsletter.
